Volume 121, Issue 12, Pages 2473-2481 (December 2014) A Randomized Clinical Trial of Intravitreal Bevacizumab versus Intravitreal Dexamethasone for Diabetic Macular Edema Mark C. Gillies, MBBS, PhD, Lyndell L. Lim, MBBS, Anna Campain, PhD, Godfrey J. Quin, MBChB, PhD, Wedad Salem, MB BS, MPH, Ji Li, MB BS, Stephanie Goodwin, BAppSc (Orthoptics) (Hons), Christine Aroney, MBBS, Ian L. McAllister, MBBS, Samantha Fraser-Bell, MBBS, PhD Ophthalmology Volume 121, Issue 12, Pages 2473-2481 (December 2014) DOI: 10.1016/j.ophtha.2014.07.002 Copyright © 2014 American Academy of Ophthalmology Terms and Conditions
Figure 1 Diagram showing the progression of patients through the study. DEX = dexamethasone; LOCF = last observation carried forward. Ophthalmology 2014 121, 2473-2481DOI: (10.1016/j.ophtha.2014.07.002) Copyright © 2014 American Academy of Ophthalmology Terms and Conditions
Figure 2 Mean best-corrected visual acuity by treatment type. Ophthalmology 2014 121, 2473-2481DOI: (10.1016/j.ophtha.2014.07.002) Copyright © 2014 American Academy of Ophthalmology Terms and Conditions
Figure 3 Bar graph showing the distribution of number of treatments given by treatment group for patients completing the 12-month follow-up visit. DEX = dexamethasone. Ophthalmology 2014 121, 2473-2481DOI: (10.1016/j.ophtha.2014.07.002) Copyright © 2014 American Academy of Ophthalmology Terms and Conditions
Figure 4 Graph showing the mean central macular thickness by treatment type for each month of follow-up. DEX = dexamethasone. Ophthalmology 2014 121, 2473-2481DOI: (10.1016/j.ophtha.2014.07.002) Copyright © 2014 American Academy of Ophthalmology Terms and Conditions